S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY

ABSTRACT:

SUBMITTER: Heeney1 M 

PROVIDER: S-EPMC10428338 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature